v3.26.1
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Income Statement [Abstract]    
Sales, net $ 222,018 $ 141,760
Cost of goods sold 69,981 83,290
Gross profit 152,037 58,470
Operating Expenses:    
Product development 328,422 1,373,351
Sales and marketing 349,004 811,537
General and administrative 17,652,467 26,638,816
Transaction costs 25,000 55,038,544
Depreciation and amortization 632,479 273,772
Total operating expenses 18,987,372 84,136,020
Loss from operations (18,835,335) (84,077,550)
Other income (expense):    
Other income (5,537) 21,390
UK R&D tax credit 1,202,554 1,251,243
Loss on initial issuance of convertible note (1,770,933)
Change in fair value of convertible note option liability 60,000 840,933
Change in fair value of warrant liabilities 360,685 200,124
Change in fair value of Earn-out Share Liability 13,016,400 38,040,000
Other expense (256,585) (244,732)
Interest expense (2,202,220) (1,808,243)
Total other income 12,175,297 36,529,782
Net loss $ (6,660,038) $ (47,547,768)
Net loss per share:    
Basic (in Dollars per share) $ (0.16) $ (1.88)
Diluted (in Dollars per share) $ (0.16) $ (1.88)
Weighted-average common stock outstanding used in per share amounts:    
Basic (in Shares) 42,806,029 25,257,473
Diluted (in Shares) 42,806,029 25,257,473
Other comprehensive income (loss):    
Foreign currency translation adjustment $ (1,386,165) $ 795,745
Comprehensive loss $ (8,046,203) $ (46,752,023)